untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-17T12:17:49Z</responseDate>
<request identifier=oai:HAL:hal-01668328v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01668328v1</identifier>
<datestamp>2017-12-22</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UNIV-REUNION</setSpec>
<setSpec>collection:UNIV-PARIS7</setSpec>
<setSpec>collection:USPC</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Extracellular microvesicle microRNAs in children with sickle cell anaemia with divergent clinical phenotypes</title>
<creator>Khalyfa, Abdelnaby</creator>
<creator>Khalyfa, Ahamed A.</creator>
<creator>Akbarpour, Mahzad</creator>
<creator>Connes, Phillippe</creator>
<creator>Romana, Marc</creator>
<creator>Lapping-Carr, Gabrielle</creator>
<creator>Zhang, Chunling</creator>
<creator>Andrade, Jorge</creator>
<creator>Gozal, David</creator>
<contributor>Protéines de la membrane érythrocytaire et homologues non-érythroides ; Université des Antilles et de la Guyane (UAG) - Institut National de la Transfusion Sanguine [Paris] (INTS) - Université Paris Diderot - Paris 7 (UPD7) - Université de la Réunion (UR) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Universidade de Lisboa - Instituto de Medicina Molecular ; Universidade de Lisboa (ULISBOA)</contributor>
<contributor>Kosair Children's Hospital Research Institute ; University of Louisville</contributor>
<description>International audience</description>
<source>ISSN: 0007-1048</source>
<source>EISSN: 1365-2141</source>
<source>British Journal of Haematology</source>
<publisher>Wiley</publisher>
<identifier>hal-01668328</identifier>
<identifier>https://hal.univ-antilles.fr/hal-01668328</identifier>
<source>https://hal.univ-antilles.fr/hal-01668328</source>
<source>British Journal of Haematology, Wiley, 2016, 174 (5), pp.786 - 798. 〈10.1111/bjh.14104〉</source>
<identifier>DOI : 10.1111/bjh.14104</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1111/bjh.14104</relation>
<language>en</language>
<subject lang=en>endothelial function</subject>
<subject lang=en> exosomes</subject>
<subject lang=en> sickle cell anaemia</subject>
<subject>[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>Sickle cell anaemia (SCA) is the most frequent genetic haemoglobinopathy, which exhibits a highly variable clinical course characterized by hyper-coagulable and pro-inflammatory states, as well as endothelial dysfunction. Extracellular microvesicles are released into biological fluids and play a role in modifying the functional phenotype of target cells. We hypothesized that potential differences in plasma-derived extracellular microvesicles (EV) function and cargo from SCA patients may underlie divergent clinical trajectories. Plasma EV from SCA patients with mild, intermediate and severe clinical disease course were isolated, and primary endothelial cell cultures were exposed. Endothelial cell activation, monocyte adhesion, barrier disruption and exosome cargo (microRNA microarrays) were assessed. EV disrupted the endothelial barrier and induced expression of adhesion molecules and monocyte adhesion in a SCA severity-dependent manner compared to healthy children. Microarray approaches identified a restricted signature of exosomal microRNAs that readily distinguished severe from mild SCA, as well as from healthy children. The microRNA candidates were further validated using quantitative real time polymerase chain reaction assays, and revealed putative gene targets. Circulating exosomal microRNAs may play important roles in predicting the clinical course of SCA, and in delineation of individually tailored, mechanistically-based clinical treatment approaches of SCA patients in the near future.</description>
<date>2016-09</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>